Casas J A, Saway P A, Villarreal I, Nolte C, Menajovsky B L, Escudero E E, Blackburn W D, Alarcón G S, Subauste C P
Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
Ann Rheum Dis. 1990 Nov;49(11):926-8. doi: 10.1136/ard.49.11.926.
A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil.
一项关于5-氟尿嘧啶治疗硬皮病的为期六个月的对照研究表明，在皮肤评分、雷诺现象和患者整体评估方面有适度益处。内脏器官和手部功能未受影响。5-氟尿嘧啶治疗的患者中常见轻度至中度毒性，但通常通过减少剂量即可缓解。两名接受5-氟尿嘧啶治疗的患者死于看似与治疗无关的原因。在使用5-氟尿嘧啶治疗的前六个月中，未观察到硬皮病有显著的临床改善。
